ESPE Abstracts (2022) 95 P1-362

12 views


1Clinic for Assessment of Adolescent Learning Difficulties, Center for Adolescent Medicine and UNESCO Chair in Adolescent Health Care, First Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; 2University Oncology Hematology Unit, First Department of Pediatrics, National and Kapodistrian University of Athens, Athens, Greece; 3Pediatric Neurology Unit, First Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; 4Faculty of Primary Education, National and Kapodistrian University of Athens, Athens, Greece; 5First Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece


Introduction – Scope: Childhood cancer has an impact on the neurocognitive functions of growing children and adolescents. The aim of this study, which is the first of its kind in Greece, was to examine the differences in neurocognitive abilities between children and adolescents survivors of brain tumors (BT), and survivors of other types of cancer.

Method: Study participants were cancer survivors aged 7 to 15 years, without any major mental health disorder, for whom ≥ 1 year had elapsed from completion of cancer treatment. Cognitive function was measured with the Hellenic (Greek) version of the Wechsler Intelligence Scale for Children-Third Edition (WISC-III) which measures full-scale intelligence qK. Mavrea1K. Mavrea1uotient (FSIQ), verbal IQ (VIQ) and practical IQ (PIQ).

Results: A total 70 childhood cancer survivors were evaluated, with an average age (±SD) of 11.29 (±2.60) years. Survivors of BT had significantly (P=. 011) lower mean (± SD) FSIQ (82.06 ± 23.45) than acute lymphoblastic leukemia (ALL) survivors (100.09 ± 20.19) or survivors of other types of cancer (108.56 ± 15.65). Regarding PIQ, survivors of BT demonstrated significantly (P=. 005) lower mean (± SD) scores (40.50 ± 14.05) than survivors of ALL (51.57 ± 9.15) or other types of cancer (54.11 ± 7.98).

Conclusion: This research demonstrated the negative impact of BT on the neurocognitive functions of cancer survivors during the sensitive developmental periods of childhood and adolescence.

Volume 95

60th Annual ESPE (ESPE 2022)

Rome, Italy
15 Sep 2022 - 17 Sep 2022

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.